Why oral morphine is not the 'gold standard' for BTcP

European Journal of Palliative Care

Volumn 16, Issue 3 SUPPL., 2009, Pages 10-12

  Davies, Andrew ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77949383679     PISSN: 13522779     EISSN: 14790793     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Portenoy RK, Forbes K, Lussier D, Hanks G. Difficult pain problems: an integrated approach. In: Doyle D, Hanks G, Cherny N, Calman K (eds). Oxford Textbook of Palliative Medicine. 3rd edition. Oxford: Oxford University Press, 2004: 438-458.
2. Davies A. Introduction. In: Davies A (ed). Cancer-related Breakthrough Pain. Oxford: Oxford University Press, 2006: 1-11.
3. Portenoy RK. Treatment of temporal variations in chronic cancer pain. Semin Oncol 1997; 5 (Suppl 16): 7-12.
4. Davies AN, Vriens J, Kennett A, McTaggart M. An observational study of oncology patients' utilisation of breakthrough pain medication. J Pain Symptom Manage 2008; 35: 406-411.
5. Skinner C, Thompson E, Davies A. Clinical features. In: Davies A (ed). Cancer-related Breakthrough Pain. Oxford: Oxford University Press, 2006: 13-22.
6. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990; 41: 273-281.
7. Gómez-Batiste X, Madrid F, Moreno F et al. Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain. J Pain Symptom Manage 2002; 24: 45-52.
8. Davies A. General principles of management. In: Davies A (ed). Cancer-related Breakthrough Pain. Oxford: Oxford University Press, 2006: 31-42.
9. Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 2008 (in press).
10. Christelis N, Filshie J. Other therapeutic interventions. In: Davies A (ed). Cancer-related Breakthrough Pain. Oxford: Oxford University Press, 2006: 97-110.
11. Mercadante S, Arcuri E. Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev 1998; 24: 425-432.
12. Bailey F, Farley A. Oral opioid drugs. In: Davies A (ed). Cancer-related Breakthrough Pain. Oxford: Oxford University Press, 2006: 43-55.
13. Freye E, Levy JV, Braun D. Effervescent morphine results in faster relief of breakthrough pain in patients compared to immediate release morphine sulfate tablet. Pain Practice 2007; 7: 324-331.
14. Mercadante S, Villari P, Ferrera P et al. Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine. J Pain Symptom Manage 2006; 32: 175-179.
15. Dale O. Opioid drugs via other routes. In: Davies A (ed). Cancer-related Breakthrough Pain. Oxford: Oxford University Press, 2006: 73-82.
16. Walker G, Wilcock A, Manderson C, Weller R, Crosby V. The acceptability of different routes of administration of analgesia for breakthrough pain. Palliat Med 2003; 17: 219-221.
17. Coluzzi PH. Sublingual morphine: efficacy reviewed. J Pain Symptom Manage 1998; 16: 184-192.
18. Pavis H, Wilcock A, Edgecombe J et al. Pilot study of nasal morphine-chitosan for the relief of breakthrough pain in patients with cancer. J Pain Symptom Manage 2002; 24: 598-602.